Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.

Busetto L, Contreras CO, Christensen MH, Garvey TW, Horn DB, McGowan B, Miller CP, Schnecke V, le Roux CW

Diabetes, obesity & metabolism26 Jul 2026Cited by 1 (Europe PMC)

PMID42503495PMCIDPMC13538786DOI10.1111/dom.71134PepBankPUB-42503495

Summary

AimsTo assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity.Materials and methodsThe phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention. This secondary, post hoc analysis assessed the proportions of participants achieving BMI 2 and/or WHtR < 0.53 targets, and percentage weight loss by anthropometric target. The association between the proportion of participants maintaining or achieving normalisation of four cardiometabolic outcomes: normoglycemia (glycated haemoglobin < 5.7% and fasting plasma glucose < 5.6 mmol/L); blood pressure (< 130/80 mmHg); triglycerides (< 1.7 mmol/L); lipids (high-density lipoprotein cholesterol ≥ 1.3 mmol/L [female] or ≥ 1.0 mmol/L [male]) and reaching anthropometric targets or change in body weight (%) was also assessed.ResultsThe proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively. Both BMI and WHtR performed similarly as indicators for all four cardiometabolic outcomes. At more stringent cut-off values, anthropometric targets were better measures than percentage weight loss.ConclusionsThe proportion of participants achieving anthropometric targets was greater with CagriSema Versus other treatments. These findings support further validation of BMI and WHtR anthropometric treatment targets and indicate a potential for indicating amelioration of clinical outcomes in obesity and a greater emphasis on target-based treatment strategies.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and no diabetes, more participants reached both BMI and waist-to-height targets at week 68 with CagriSema (30.3%) than with semaglutide (19.1%).
In plain wordsIn adults with overweight or obesity, more people reached both body-size targets with CagriSema (30.3%) than with semaglutide (19.1%).
Peptide
Cagrilintide
Outcome
IncreaseProportion reaching BMI < 27 kg/m2 and WHtR < 0.53 at week 68, CagriSema vs semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
CagriSema 2.4 mg/2.4 mg once weekly · 68 weeksAs given in this study (human).
Measurements
Participants reaching both targets
30.3%
CagriSema
Participants reaching both targets
19.1%
semaglutide
Source sentences
Summary
The proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.
Show in the study text Report a problemFND-4250349501
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and no diabetes, 9.0% reached both BMI and waist-to-height targets at week 68 with cagrilintide versus 3.3% with placebo.
In plain wordsIn adults with overweight or obesity, 9.0% reached both body-size targets with cagrilintide alone versus 3.3% with placebo.
Peptide
Cagrilintide
Outcome
IncreaseProportion reaching BMI < 27 kg/m2 and WHtR < 0.53 at week 68, cagrilintide vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
cagrilintide 2.4 mg once weekly · 68 weeksAs given in this study (human).
Measurements
Participants reaching both targets
9%
cagrilintide
Participants reaching both targets
3.3%
placebo
Source sentences
Summary
The proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.
Show in the study text Report a problemFND-4250349504
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, 19.1% of participants on semaglutide 2.4 mg reached both BMI < 27 kg/m2 and WHtR < 0.53 at week 68, versus 3.3% on placebo.
In plain wordsIn adults with obesity, 19.1% on semaglutide reached both body size targets at week 68, against 3.3% on placebo.
Peptide
Semaglutide
Outcome
IncreaseAchieving BMI < 27 kg/m2 and WHtR < 0.53 at week 68 (semaglutide)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg · 68 weeksAs given in this study (human).
Measurements
Proportion achieving both targets
19.1%
semaglutide 2.4 mg
Source sentences
Summary
The proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.
Show in the study text Report a problemFND-4250349506

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and no diabetes, more participants reached both BMI and waist-to-height targets at week 68 with CagriSema (30.3%) than with cagrilintide (9.0%).
In plain wordsIn adults with overweight or obesity, more people reached both body-size targets with CagriSema (30.3%) than with cagrilintide alone (9.0%).
Peptide
Cagrilintide
Outcome
IncreaseProportion reaching BMI < 27 kg/m2 and WHtR < 0.53 at week 68, CagriSema vs cagrilintide
Study
n: not reported in source
Comparator
Cagrilintide 2.4 mg
Outcome group
Body weight · Metabolic and weight
Measurements
Participants reaching both targets
30.3%
CagriSema
Participants reaching both targets
9%
cagrilintide
Source sentences
Summary
The proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Show in the study text Report a problemFND-4250349502
05HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and no diabetes, more participants reached both BMI and waist-to-height targets at week 68 with CagriSema (30.3%) than with placebo (3.3%).
In plain wordsIn adults with overweight or obesity, more people reached both body-size targets with CagriSema (30.3%) than with placebo (3.3%).
Peptide
Cagrilintide
Outcome
IncreaseProportion reaching BMI < 27 kg/m2 and WHtR < 0.53 at week 68, CagriSema vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Participants reaching both targets
30.3%
CagriSema
Participants reaching both targets
3.3%
placebo
Source sentences
Summary
The proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Show in the study text Report a problemFND-4250349503
06HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, 30.3% of participants on CagriSema reached both BMI < 27 kg/m2 and WHtR < 0.53 at week 68, the highest share of the four arms.
In plain wordsIn adults with obesity, 30.3% on the CagriSema combination reached both body size targets at week 68, more than with the other treatments.
Peptide
Semaglutide
Outcome
IncreaseAchieving BMI < 27 kg/m2 and WHtR < 0.53 at week 68 (CagriSema)
Study
n: not reported in source
Comparator
Semaglutide, cagrilintide or placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Proportion achieving both targets
30.3%
CagriSema
Source sentences
Summary
The proportion of participants achieving both BMI 2 and WHtR < 0.53 targets at week 68 was 30.3%, 19.1%, 9.0%, and 3.3% in participants who received CagriSema, semaglutide, cagrilintide, or placebo respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The proportion of participants achieving anthropometric targets was greater with CagriSema Versus other treatments.
Summary · context
The phase 3a, 68-week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4250349505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.